Physician profile
Amanda Canova
NPI 1164468161
$1,608.63
in general payments reported to CMS, 2019-2025
25 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $61.58 · 2021: $184 · 2022: $199 · 2023: $515 · 2024: $127 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.33 |
| Education | $356.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $385.47 | 2019-2025 | Veozah |
| Abbvie INC. | $248.89 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Millicent US INC | $153.43 | 2019-2025 | Intrarosa, Femring |
| Therapeuticsmd, INC. | $88.76 | 2019-2021 | |
| Exeltis, USA INC. | $80.67 | 2021-2025 | Slynd |
| Ethicon US, LLC | $71.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.72 | 2021-2025 | |
| Allergan, INC. | $54.57 | 2019-2020 | |
| Organon LLC | $50.84 | 2023-2024 | Nexplanon |
| Evofem Biosciences, INC. | $49.28 | 2022-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $49.02 | 2019-2020 | |
| Lupin INC. | $47.48 | 2019-2020 | |
| Exact Sciences Corporation | $47.37 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $46.22 | 2023-2025 | Myfembree |
| Bausch Health US, LLC | $27.97 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.20 | 2019-2022 | |
| Meditrina | $24.28 | 2023 | |
| Amgen INC. | $15.00 | 2019 | |
| Dysis Medical, INC. | $14.99 | 2022 | |
| Avion Pharmaceuticals | $14.75 | 2021 | |
| Mayne Pharma Commercial LLC | $14.29 | 2022 | |
| Minerva Surgical, INC | $13.96 | 2019 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.03 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Canova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.